| Recruitment status | Preinitiation |
| Unique ID issued by UMIN | UMIN000021968 |
| Receipt No. | R000025323 |
| Official scientific title of the study | A randomized crossover study between insulin glulisine and insulin aspart in patients with type 1 diabetes |
| Date of disclosure of the study information | 2016/04/18 |
| Last modified on | 2016/04/18 (Ver. 1) |
| Basic information | ||
| Official scientific title of the study | A randomized crossover study between insulin glulisine and insulin aspart in patients with type 1 diabetes | |
| Title of the study (Brief title) | A randomized crossover study between insulin glulisine and insulin aspart in patients with type 1 diabetes | |
| Region |
|
|
| Condition | ||
| Condition | type 1 diabetes | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | comparison of the the speed of the effect between insulin glulisine and insulin aspart
|
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | area under curve of blood glucose level between before meal and three hours after meal |
| Key secondary outcomes | peak level of blood glucose after meal,
average and standard deviation of blood glucose level, frequency of hypoglycemia, impression from use |
| In outcomes field, the entry of just a few words such as "safety" or "efficiency" will not be accepted. Specify the name of outcome measures, including the time when you plan to measure. Usually, only one primary outcome is accepted. Write the other outcomes in "secondary outcomes" field. |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Cross-over |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Open -no one is blinded |
| Control | Active |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | insulin glulisine injection for six days | |
| Interventions/Control_2 | insulin aspart injection for six days | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| In interventions field, include the details of interventions, such as duration, amount, and frequency. If the intervention includes prescription or use of medical devices, duration is required. |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | # HbA1c above 5% under 9%
# diabetes duration above 2 years # SAP (sensor augmented insulin pump) therapy # carb count method |
|||
| Key exclusion criteria | # pregnant
# oral steroid therapy # significant obesity # advanced diabetes coomplication |
|||
| Target sample size | 25 | |||
| Research contact person | |
| Name of lead principal investigator | Kawamura Tomoyuki |
| Organization | Osaka City University |
| Division name | Pediatrics |
| Address | 1-5-7 Asahi machi, Abenoku,Osaka |
| TEL | 06-6645-3816 |
| kawam@med.osaka-cu.ac.jp | |
| Public contact | |
| Name of contact person | Hotta Yuko |
| Organization | Osaka City University |
| Division name | Pediatrics |
| Address | 1-5-7 Asahi machi, Abenoku,Osaka |
| TEL | 06-6645-3816 |
| Homepage URL | |
| kky_hotta@yahoo.co.jp | |
| Sponsor | |
| Institute | Osaka City University
Pediatrics |
| Institute | |
| Department | |
| Sponsor means an organization that is responsible for plan, deployment and report of the research including funding management. It doesn't mean funding agency". Therefore, all clinical trial should have the one. |
| Funding Source | |
| Organization | Osaka City University
Pediatrics |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Preinitiation | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000025323 |